Who Really Put Peptides on the Restricted List — And Why They’re Coming Back

// Market Update · Regulatory History · FDA Framework · Titanborn Research

In September 2023, the FDA restricted compounding pharmacies from preparing 19 of the most widely used therapeutic peptides. By April 2026, most of those same peptides were on their way back. Understanding what happened between those two dates explains everything about why the gray market exists — and what responsible sourcing looks like inside it.

First, the Thing Almost Every Headline Gets Wrong

The 2023 action was not a ban on owning, selling, or researching peptides. It was specifically about compounding — the practice of licensed pharmacies preparing customized medications for patients. The restriction stopped compounding pharmacies from preparing these peptides under physician prescription. It did not criminalize the compounds themselves, and it did not directly govern the research-use-only market. So “peptides were banned” is shorthand that misleads. The precise version: these peptides were restricted from pharmacy compounding. That distinction matters for understanding everything that followed.

How the FDA’s Compounding Bulks List Works

Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare medications using bulk drug substances — but only those the FDA has vetted. Since 2017 the agency has run an interim policy sorting nominated substances into categories:

Category 1 — substances the FDA does not intend to act against compounders for using. Effectively permitted for compounding under physician prescription while evaluation continues.

Category 2 — substances the FDA considers to present significant safety concerns. Compounding pharmacies cannot legally use these. This is the do-not-compound bucket.

Category 3 — substances under evaluation that need further review before assignment.

Here is the detail most people do not know: substances get onto the evaluation list because someone nominates them. Nominations can come from physicians, researchers, pharmacies, advocacy groups, or private companies. The FDA then evaluates the nominated substance and assigns it to a category. That nomination mechanism becomes important later.

September 2023 — The Restriction That Changed Everything

In September 2023, under the Biden administration, the FDA moved 19 peptide or peptide-related bulk substances into Category 2 — effectively restricting compounding pharmacies from preparing them. The list included BPC-157, TB-500, Thymosin Alpha-1, Ipamorelin, CJC-1295, Epitalon, GHK-Cu, Selank, Semax, and others that physicians had prescribed and pharmacies had prepared for years.

The FDA’s stated rationale centered on four concerns: immunogenicity risk, peptide-related manufacturing impurities, difficulty fully characterizing the active ingredient, and insufficient large-scale human safety data. It is worth being precise here, because “significant safety concerns” sounds more alarming than the actual reasoning: three of those four concerns are about manufacturing quality and characterization — not findings that the molecules are toxic. The agency cited a lack of population-level clinical evidence, which means “not enough study,” not “studied and found dangerous.” Hold that thought — it becomes the entire argument later.

The response from clinicians, compounding associations, and members of Congress was immediate. Legal challenges were filed. Clinicians who had used these peptides for years argued that no specific safety signal justified the broad restrictions for most of the affected substances. But the restriction held — and the consequences were predictable.

The Unintended Consequence — The Gray Market Explosion

When compounding pharmacies could no longer legally prepare these peptides, patients who had been using them faced a choice: stop, or find another source. The demand did not disappear. It redirected.

Within months of the September 2023 restrictions, the gray-market research-chemical sector — vendors selling peptides as research-use-only products with no prescription required — saw rapid growth. Patients who had been getting compounded peptides from licensed pharmacies with physician oversight were now ordering from websites with no quality standards, no sterility testing, no oversight, and no accountability.

This was not unpredictable. It was the documented result of removing regulated access without addressing underlying demand. HHS Secretary Robert F. Kennedy Jr. later acknowledged this directly, stating that the Category 2 designations effectively created and accelerated the very gray market they were designed to prevent.

The 40-Amino-Acid Line — A Distinction Worth Understanding

There is a separate piece of regulatory structure that often gets confused with the 2023 restrictions, so it is worth getting right. Under the Biologics Price Competition and Innovation Act, the legal dividing line between a “peptide” and a “biologic” is length: chains of 40 or fewer amino acids are classified as small-molecule peptides and fall under traditional drug-compounding law. Chains exceeding 40 amino acids are classified as biologics, which require a Biologics License Application — a far higher regulatory burden — and cannot be prepared by compounding pharmacies at all.

When a 2020 framework change took effect, it reclassified certain larger molecules as biologics. That move made a small number of larger peptides — such as tesamorelin and human chorionic gonadotropin (hCG) — ineligible for compounding by reclassifying them as biologic products. But this is the key point most sources get wrong: the commonly researched small peptides were not swept up by the biologics reclassification. BPC-157 (15 amino acids), Semax (7), Epitalon (4), and similar compounds all sit well under the 40-amino-acid line, so they remain peptides — not biologics. Those compounds reached Category 2 in 2023 through the safety-nomination route described above, not through the biologics framework. Two separate mechanisms, often conflated.

Who Nominated the Peptides — And What Happened Next

Here is one of the more revealing facts in this regulatory history: many of the peptides placed in Category 2 were nominated by private parties — not initiated by the FDA independently. Nominators submitted petitions, and the FDA’s process assigned the substances to a category based on the submitted evidence and its own review.

In April 2026, the FDA announced that 12 peptides would be removed from Category 2. The stated reason was straightforward: the nominations had been withdrawn. When the nominations supporting a Category 2 designation are withdrawn, the basis for maintaining that designation is removed. The withdrawal also signals that the FDA is reconsidering whether the original safety concerns hold up.

It is worth noting what this sequence demonstrates about how the nomination process works. Parties with financial interests in the therapeutic-peptide market have standing to nominate compounds for restriction — and standing to withdraw those nominations. The FDA process responds to what it receives. The regulatory outcome reflects both the scientific evidence and the strategic decisions of the parties submitting it.

February 27, 2026 — Kennedy on Rogan

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. appeared on the Joe Rogan Experience and signaled that roughly 14 of the 19 restricted peptides would move back toward Category 1 — restoring a legal pathway through licensed compounding pharmacies under physician prescription. Kennedy was explicit about his view: he called himself a “big fan” of peptides, said he had taken them himself, and characterized the Biden-era restrictions as having driven patients toward unregulated sources. The move fits within his broader “Make America Healthy Again” agenda.

The regulatory mechanics followed quickly. On April 15, 2026, the FDA announced it would remove 12 peptides from Category 2 — effective April 22, 2026, seven calendar days later — because the nominations had been withdrawn. The 12 included BPC-157, TB-500, GHK-Cu (injectable), Semax, Epitalon, KPV, MOTS-c, DSIP, DiHexa, LL-37, PEG-MGF, and Melanotan II. (Several others, including CJC-1295, Ipamorelin, and Selank, had already come off Category 2 in a 2024 round of withdrawn nominations.)

What “Removed From Category 2” Actually Means — Read This Carefully

This is where the headlines fail hardest. “Peptides are legal again” is not accurate. Removal from Category 2 is procedural — it is not approval, and it does not by itself make a peptide eligible for compounding.

Multiple regulatory-law analyses have stressed the same point: removal from Category 2 does not equal inclusion on the 503A Bulks List, and reclassification does not equal FDA approval. The substances enter a transitional state — no longer formally “do not compound,” but not yet cleared for compounding either. None of these peptides has a New Drug Application approval. Category status governs compounding legality only; it does not establish proven safety, proven efficacy, or standardized dosing.

The real decision points are the advisory-committee reviews. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to consider seven peptides — including BPC-157 (for ulcerative colitis), TB-500 and KPV (wound healing), MOTS-c, DSIP, and Semax (cerebral ischemia) — for potential inclusion on the 503A Bulks List. A second PCAC meeting is scheduled before the end of February 2027 to review five additional peptides, including GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF. Until those reviews conclude and the FDA issues final determinations, compounding pharmacies cannot resume production at scale.

What This Means for Researchers in 2026

The regulatory shift creates a clearer landscape going forward — two distinct tracks rather than a gray zone with no regulated alternative.

Track 1 — Regulated compounding. Physician prescription, licensed 503A pharmacy, pharmaceutical-grade manufacturing, medical oversight. Once the PCAC reviews are complete and the FDA issues final determinations, the returning peptides may become legally accessible through this channel. Higher cost, prescription required, medical accountability built in.

Track 2 — Research use only. Laboratory and in-vitro research purposes, no prescription required, quality varies significantly by vendor, no medical oversight. This track is unaffected by the reclassification — it existed before the 2023 restrictions and continues independently of compounding-pharmacy regulations.

These two tracks do not intersect. A research-use-only peptide cannot be relabeled as a compounded pharmaceutical, and a compounded medication cannot be sold as a research chemical. The legal frameworks are separate by design. For researchers operating in the RUO framework, the practical implication is simple: the regulated medical access removed in 2023 is being restored, which is good for patients who need oversight — but it does not change the research-use-only market or the standards that should govern sourcing within it.

What Responsible Sourcing Looks Like In This Context

The history above explains why the gray market developed the way it did. It does not excuse the quality problems that developed within it. When regulated access was removed and demand redirected to unverified vendors, the result was predictable — a market full of operators with no accountability serving customers who had nowhere else to go.

Step back from the politics and one theme runs through every chapter of this story. The FDA’s original concern was manufacturing quality and characterization — can you confirm what is actually in the vial, and is it clean? The gray market the restriction created made that concern worse, not better. And even the case for reversal rests on the idea that verified, quality-controlled supply is safer than unverified supply. Every side of this debate — the regulators who restricted, the critics who challenged, and the Secretary who reversed — ultimately agrees on the same premise: where peptides come from, and whether they are properly tested, is what actually matters.

The answer is not to abandon the research-use-only framework. It is to hold vendors within it to a higher standard: independent testing from accredited laboratories, batch-specific documentation, public verification of results, and accountability that does not depend on regulatory enforcement. That is why Titanborn Research was built the way it was — not because the regulatory environment requires it, but because the researchers who use these compounds deserve to know exactly what they are working with.